Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vitamin D Supplementation in Addition to Pegylated Interferon Plus Ribavirin in Null-Responders Patients With Chronic Viral Hepatitis C Genotype 1 or 4
NCT01226446Phase 2Completed
- Sponsor
- ANRS
- Start
- Nov 2010
- Primary completion
- Feb 2012
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vitamin d in hepatitis C (HCV), sponsored by ANRS. Primary endpoint: Negativity of HCV RNA below 12UI/mL at 12 weeks. Started Nov 2010; status: completed.
02
Drugs
vitamin d
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01226446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01226446.